Peer reviewed publications on the use of TICL for refractive correction in corneal ectasia
| Author(s) year, reference*PubMed, Scopus and science | Number of eyes, follow-up for each procedure | Preoperative data | Postoperative data | Complications | Final outcomes |
| Kamiya et al, J Refract Surg, 200844 | 2 eyes (2 patients), 12 months | Case 1: −10.00–6.00×100 Case 2: −8.00–2.00×100 | Case 1: +0.50–1.00×90 Case 2: −0.25–1.25×100 | – | – |
| Alfonso et al, J Refract Surg, 200845 | 25 eyes (16 patients), 12 months | Sph: −3.00 to −18.00 D Cyl: −0.50 to −3.00 D | UCDVA: 0.17±0.19 CDVA: 0.12±0.12 | – | SI: 1.05 EI: 0.98 |
| Alfonso et al, J Cataract Refract Surg, 201046 | 30 eyes (21 patients), 12 months | Sph: −5.38±3.26 D Cyl: −3.48±1.24 D | Mean UDVA: 0.81±0.20 Mean CDVA: 0.83±0.18 | – | SI: 1.16 EI: 1.07 |
| Kamiya et al, Graefes Arch Clin Exp Ophthalmol, 201147 | 27 eyes (14 patients), 6 months | SER: −10.11±2.46 D Cyl: −3.03±1.58 D | UCDVA: −0.09±0.16 CDVA: −0.15±0.09 | – | SI: 1.12±0.18 EI: 1.01±0.25 |
| Hashemian et al, Clin Exp Optom, 20135 | 22 eyes (14 patients), 6 months | Sph: −4.98±2.63 D Cyl: −2.77±0.99 D | Sph: −0.33±0.51 D Cyl: −1.23±0.65 D UCVA: 0.76±0.23 | – | SI: 1.40±0.32 EI: 1.24±0.34 |
| Kymionis et al, Ophthalmic Surg Lasers Imaging, 201148 | 1 patient, 3 months | UDVA: C.F CDVA: 0.7 log MAR | UCVA: 0.3 CDVA: 0.2 | – | – |
| Fadlallah et al, J Refract Surg, 20139 9 | 16 eyes (10 patients), 6 months after CXL, 6 months after TICL | Mean UDVA: 1.67±0.49 CDVA: 0.15±0.06 log MAR SE: −7.24±3.53 D | Mean UDVA: 0.17±0.06 CDVA: 0.12±0.04 SE: −0.89±0.76 D | – | SI: 1.08±0.13 EI: 0.97±0.08 |
| Coskunseven et al, Am J Ophthalmol, 200749 | 3 eyes (2 patients). TICL minimum 6 months post-Intacs, 12 months | SE: −18.50±2.61 D | SE: 0.42 D | – | – |
| Fernandez-Vega L et al, Invest Ophthalmol Vis, 201050 | 18 eyes (14 patients), 6 months | UDVA: 0.1±0.05 (decimal) CDVA: 0.7±0.19 (decimal) | UDVA: 0.6±0.19 CDVA: 0.8±0.14 | – | – |
| Navas et al, Int Ophthalmol, 201251 | 11 eyes (8 patients), 38.18±18.7 months | SE: −10.52±5.88 D UDVA: 1.31±0.37 log MAR CDVA: 0.28±0.14 log MAR | SE: −0.68±0.45 D UDVA: 0.14±0.04 CDVA: 0.16±0.08 | – | SI: 1.28 EI: 0.88 |
| Coskunseven et al, J Cataract Refract Surg, 201352 | 14 eyes (9 patients), 12 months | UDVA: 0.01 (decimal) CDVA: 0.14 (decimal)SE: −16.40±3.56 D | UDVA: 0.44 CDVA: 0.57 SE: −0.80±1.02 D | – | – |
| Iovieno et al, Eur J Ophthalmol, 201353 | 7 eyes (7 patients), 12.8±8.8 months | UCDVA: 1.18±0.4 SE: −8.09±3.77 D | UCDVA: 0.2±0.1 SE: −0.33±0.54 | – | – |
| Kurian et al, J Cataract Refract Surg, 201254 | 10 eyes (7 patients), 6 months | Mean SE: −7.21±2.25 | Mean SE: −0.44±1.21 D | – | EI: 0.72 SI: 1.13 |
| Ali M et al, Cornea, 201455 | 29 eyes (16 patients), 3 months | CH: 9.2±1.4 mm Hg CRF: 8.4±1.6 mm Hg | CH: 8.8±1.3 mm Hg CRF: 8.8±1.6 mm Hg | – | – |
| Alió et al, J Cataract Refract Surg, 20146 | 20 eyes received an iris claw phakic IOL, and 28 eyes a PC phakic IOL, 36 months | Mean SE: −9.31±4.20 (decimal) UDVA: 0.08±0.09 CDVA: 0.77±0.2 | Mean SE: −0.46±0.88 (decimal) UDVA: 0.71±0.26 CDVA: 0.87±0.98 | – | – |
| Antonios et al, J Ophthalmol, 201556 | 30 eyes (19 patients), 2 years. | UDVA: 1.57±0.56 CDVA: 0.17±0.08 | UDVA: 0.17±0.06 CDVA: 0.11±0.05 | – | SI: 1.08±0.13 EI: 0.97±0.08 |
| Kamiya et al, Br J Ophthalmol, 20152 | 21 eyes (11 patients), 3 years | SE: −9.70±2.33 D UCVA: 1.46±0.15 log MAR | UDVA: −0.06±0.11 CDVA: −0.12±0.09 | – | – |
| Dirani et al, Eur J Ophthalmol, 201457 | 11 eyes (7 patients), 6 months | UCVA: 1.47±0.38 log MAR CDVA: 0.50±0.22 log MAR | UCVA: 0.27±0.20 CDVA: 0.19±0.11 | – | – |
| Kummelil et al, SYMPOSIUM:KCN, 201358 | 10 eyes (7 patients), 6 months | Mean SE: −7.21±2.25 D | Mean SE: −0.44±1.21 D | – | EI: 0.72 SI: 1.13 |
| Park et al, Korean J Ophthalmol, 201359 | Case report, 37-year-old man, 20 months | Refraction: −12.0–3.5×30 | Refraction: −1.75×180 | – | – |
| Camoriano et al, J Cataract Refract Surg, 201260 | 10 eyes (5 patients), 3 years | Mean SE: −6.71±0.9 D CDVA: 0±0.03 log MAR | SE: −0.58±0.1 D CDVA: −0.04±0.03 | 1 eye requiring removal and replacement of the toric phakic IOL | – |
| Emara et al, J Cataract Refract Surg, 201561 | 11 eyes (9 myopic, 2 hyperopic), 16.8 months (in myopic eyes) | Mean SE: −11.07 D, SE: +8.75 D, CDVA: 20/171 for myopia CDVA: 20/130 for hyperopia | Mean SE: −1.40 D CDVA: 20/51 | 2 hyperopic eyes | – |
| Prakash et al, BMJ, 2015.62 | Case report, 35-year-old man | Right UCVA: 4/60 CDVA: 6/18 | Refraction: +0.50–0.50×85, UDVA: 6/12, CDVA: 6/9 | – | – |
| Alfonso et al, J Cataract Refract Surg, 201163 | 40 eyes (31 patients), 6 months | UDVA (decimal): 0.11±0.05 CDVA: 0.56±0.23 Sph: −7.56±7.27 Cyl: −4.19±2.08 | UDVA (decimal): 0.50±0.27 CDVA: 0.73±0.20 SE: −1.19±1.33 D | – | EI: 0.88 SI: 1.28 |
| Shaheen et al, Cornea, 20141 | 16 eyes (n: 11), 3 years | UDVA: 0.63 CDVA: 0.56 (decimal) | UDVA: 0.88 CDVA: 0.89 | – | – |
CDVA, corrected distance visual acuity; CF, Count Fingers; CH, corneal hysteresis; CRF, corneal resistance factor; CXL, corneal collagen crosslinking; Cyl, cylinder; EI, efficacy index; log MAR, logarithm of the minimum angle of resolution; IOL, intra ocular lens; MCDVA, mean corrected distance visual acuity; MUDVA, mean uncorrected distance visual acuity; MSE, manifest spherical equivalent; PC, posterior chamber; SE, spherical equivalent; SER, spherical equivalent refraction; SI, safety index; Sph, sphere; TICL, toric implantable collamer lens; UCDVA, uncorrected distance visual acuity; UCVA, uncorrected visual acuity; UDVA, uncorrected distance visual acuity.